Spark R F, Pallotta J, Naftolin F, Clemens R
Ann Intern Med. 1976 May;84(5):532-7. doi: 10.7326/0003-4819-84-5-532.
Fifteen patients with galactorrhea-amenorrhea syndromes were studied before, during, and after treatment with bromergocryptine. Galactorrhea and amenorrhea were noted after pregnancy (6 patients), after oral contraceptive therapy (5 patients), and in association with pituitary adenoma (4 patients). Before treatment prolactin values were elevated ranging from 27 to 125 ng/ml, while luteinizing hormone and progesterone levels failed to show ovulatory peaks or luteal phase progression. Eleven patients had luteinizing hormone-releasing hormone tests before therapy. Response was normal in 8, subnormal in 2 pituitary adenoma, and supranormal in 1 patient with premature ovarian failure. Treatment with bromergocryptine was associated with a lowering of serum prolactin, cessation of lactation in all, and return of ovulatory menses in 14 of 15 patients. All relapsed when therapy was discontinued. Four patients became pregnant while on therapy. Long-term bromergocryptine therapy is effective for all forms of galactorrhea-amenorrhea syndromes studied.
对15例溢乳-闭经综合征患者在使用溴隐亭治疗前、治疗期间及治疗后进行了研究。溢乳和闭经出现在妊娠后（6例）、口服避孕药治疗后（5例）以及与垂体腺瘤相关时（4例）。治疗前催乳素值升高，范围为27至125纳克/毫升，而促黄体生成素和孕酮水平未显示排卵高峰或黄体期进展。11例患者在治疗前进行了促黄体生成素释放激素试验。8例反应正常，2例垂体腺瘤患者反应低于正常，1例卵巢早衰患者反应高于正常。溴隐亭治疗使血清催乳素降低，所有患者泌乳停止，15例患者中有14例恢复排卵性月经。停药后所有患者均复发。4例患者在治疗期间怀孕。长期溴隐亭治疗对所研究的所有形式的溢乳-闭经综合征均有效。
